1 | Vero E6, RCB0001 Vero
RCB0988 CACO-2
Calu-3
RCB2202 293T
RCB1366 HuH-7 | Vero E6
Caco-2
Calu-3
HEK293T
Huh7 | In Vitro and Animal Models for SARS-CoV-2 research |
2 | Vero E6
RCB0001 Vero
RCB1366 HuH-7
RCB2202 293T
RCB0098 A549, RCB3677 A549
EFKB3 | Vero E6
Vero
HUH 7.0
293T
A549
EFKB3 | Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States |
3 | RCB0001 Vero
RCB0007 HeLa, RCB3680 HeLa
RCB2202 293T
RCB1366 HuH-7
| Vero
HeLa
HEK293T/F
Huh7 | A Thermostable mRNA Vaccine against COVID-19 |
4 | RCB1637 293
RCB2202 293T
RCB0098 A549, RCB3677 A549
RCB0218 MRC-5, known PDL
Vero E6, RCB0001 Vero
Vero 81
RCB0007 HeLa, RCB3680 HeLa
RCB1366 HuH-7 | 293
293T
A549
MRC5
Vero E6
Vero 81
HeLa
Huh7 | Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV |
5 | RCB1648 Hep G2
RCB1366 HuH-7
RCB2202 293T
RCB0001 Vero
CHO
RCB0995 MDCK
| HepG2
Huh-7
293T
Vero
CHO
MDCK | Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 |
6 | Vero E6, RCB0001 Vero
RCB1366 HuH-7
| Vero E6
Huh-7 | Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway |
7 | Vero E6, RCB0001 Vero
RCB1366 HuH-7 | Vero E6
Huh-7 | Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway |
8 | Vero E6, RCB0001 Vero
RCB1366 HuH-7
| Vero E6
Huh-7 | Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) |
9 | Vero E6, RCB0001 Vero
RCB1366 HuH-7 | Vero E6
Huh-7 | A pneumonia outbreak associated with a new coronavirus of probable bat origin |
10 | RCB1637 293
RCB1366 HuH-7
RCB1423 BHK-21
Vero E6, RCB0001 Vero | HEK293
Huh-7
BHK21
Vero-E6 | Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKKε |
11 | RCB0007 HeLa, RCB3680 HeLa
RCB2202 293T
RCB1423 BHK-21
RCB0988 CACO-2 | HeLa
293T
BHK-21
Caco-2 | COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome |
12 | RCB0988 CACO-2 | Caco-2 | Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |
13 | RCB0988 CACO-2 | Caco-2 | A metabolic handbook for the COVID-19 pandemic |
14 | RCB2202 293T
RCB0098 A549, RCB3677 A549
BHK
RCB0988 CACO-2
RCB1366 HuH-7
PK-15 | 293T
A549
BHK
Caco-2
Huh-7.5
PK-15 | Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses |
15 | RCB2202 293T
RCB0098 A549, RCB3677 A549 | HEK293T
A549 | Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza |
16 | RCB2202 293T
RCB0007 HeLa, RCB3680 HeLa
Calu-3
RCB0218 MRC-5, known PDL | HEK293T
HeLa
Calu-3
MRC-5 | Cell entry mechanisms of SARS-CoV-2 |
17 | RCB2202 293T
HEK293F
RCB0007 HeLa, RCB3680 HeLa
RCB0218 MRC-5, known PDL | HEK293T
HEK293F
HeLa
MRC5 | Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry |
18 | RCB1366 HuH-7
Huh-7.5 | Huh-7
Huh-7.5 | Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication |
19 | RCB0994 MA104
RCB1637 293 | MA104
HEK293 | TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes |
20 | RCB0218 MRC-5, known PDL | MRC-5 | Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells |
21 | Fcwf-4
A72
RCB0995 MDCK
DH82 | Fcwf-4
A72
MDCK
DH82 | Establishment of a Virulent Full-Length cDNA Clone for Type I Feline Coronavirus Strain C3663 |
22 | GES-1
RCB1189 THP-1,RCB3686 THP-1 | GES-1
THP-1 | Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels |